Fig. 2From: Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areasPercentage of new users of glucagon-like peptide-1 analogues (a) and dipeptidyl peptidase-4 inhibitors (b) by activeBack to article page